Evercore ISI lowered the firm’s price target on AbbVie (ABBV) to $232 from $233 and keeps an Outperform rating on the shares. The analyst adjusted estimates in a Q1 preview note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- CollPlant announces termination of development agreement with AbbVie
- AbbVie announces results from Phase 2 IMGN853-0420 trial
- The Week That Was, The Week Ahead: Macro and Markets, April 12
- AbbVie Stock Forecast: Trending Buy Calls From Analysts
- AbbVie Stock Forecast: Trending Moderate Buy Among Analysts